Absence of effect of telbivudine on cardiac repolarization: Results of a thorough QT/QTc study in healthy participants

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1436-1446

  Poordad, Fred ^a   Zeldin, Gillian ^b   Harris, Stuart I ^c   Ke, June ^b   Xu, Limin ^d   Mayers, Douglas ^d   Zhou, Xiao Jian ^d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SeaView Research   (United States)

^d Idenix Pharmaceuticals Inc   (United States)

Author keywords

Cardiac repolarization; Pharmacodynamics; Pharmacokinetics; QT QTc interval; Telbivudine

Indexed keywords

MOXIFLOXACIN; PLACEBO; TELBIVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART REPOLARIZATION; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY MASS INDEX; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES; SEX CHARACTERISTICS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 71449093977     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337943     Document Type: Article

References (28)

1. Bryant ML, Bridges EG, Placidi L., et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 2001 ; 45: 229-235. (Pubitemid 32039120)
2. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004 ; 40: 719-726.
3. Lai CL, Leung N., Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 ; 129: 528-536. (Pubitemid 41096641)
4. Lai CL, Gane E., Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 ; 357: 2576-2588.
5. Chan HL, Heathcote EJ, Marcellin P., et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007 ; 147: 745-754.
6. Tyzeka [prescription information]. 2009. http://www.pharma.us.novartis. com/product/pi/pdf/tyzeka.pdf
7. Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother. 2006 ; 50: 874-879.
8. Zhou XJ, Swan S., Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2007 ; 51: 4231-4235. (Pubitemid 350209870)
9. Bass AS, Tomaselli G., Bullingham R III, Kinter LB Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods. 2005 ; 52: 12-21.
10. Pater C. Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities. Curr Control Trials Cardiovasc Med. 2005 ; 6: 1-13.
11. Shah RR Pharmacogenetic aspects of drug-induced Torsade de Pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. 2004 ; 27: 145-172.
12. Cubeddu LX QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003 ; 10: 452-457.
13. Ich E. 14 Step 5. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Federal Register. 2005 ; 70: 61134-61135.
14. Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008 ; 52: 2521-2528.
15. Zhou XJ, Fielman BA, Lloyd DM, Chao GC, Brown NA Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother. 2006 ; 50: 2309-2315.
16. Ich E. 14 Step 2. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2004. http://www.fda.gov/ohrms/dockets/dockets/04d0377/04D-0377-EC7-Attach-1.pdf
17. Ich E. 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions & answers. 2008. http://www.fda.gov/Cder/Guidance/8466fnl.pdf
18. Avelox [prescription information]. 2008. http://www.univgraph.com/bayer/ inserts/avelox.pdf
19. Garnett CE, Beasley N., Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 ; 48: 13-18.
20. Ayalasomayajula S., Yeh CM, Vaidyanathan S., et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol. 2008 ; 48: 799-811. (Pubitemid 351871965)
21. Hulhoven R., Rosillon D., Bridson WE, Meeus MA, Salas E., Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther. 2008 ; 30: 260-270.
22. Iwamoto M., Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48: 726-733.
23. Darp B., Nebout T., Sager PT Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006 ; 46: 498-507.
24. Al Hamoudi W., Lee SS Cirrhotic cardiomyopathy. Ann Hepatol. 2006 ; 5: 132-139.
25. Moller S., Henriksem JH Cardiovascular complications of cirrhosis. Gut. 2008 ; 57: 268-278.
26. Zambruni A., Trevisani F., Caraceni P., Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006 ; 44: 994-1002.
27. Carey EJ, Douglas DD, Mulligan DC, et al. Lack of association between Mayo end-stage liver disease score and QTc interval. Am J Gastroenterol. 2001 ; 96 (suppl). Abstract 369.
28. Puthumana L., Chaudhry V., Thuluvath PJ Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol. 2001 ; 35: 733-738.